Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.

Cancer Chemother Pharmacol · 2025 · PMC11860999 · PMID 39998586

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

However, a positive trend was observed for the response rate for all exposure quartiles.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.